155 related articles for article (PubMed ID: 21950810)
21. Proton pump inhibitor influence on reflux in Barrett's oesophagus.
Smythe A; Troy GP; Ackroyd R; Bird NC
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):881-7. PubMed ID: 18794602
[TBL] [Abstract][Full Text] [Related]
22. Strategy for prevention of cancers of the esophagus.
Akiyama J; Alexandre L; Baruah A; Buttar N; Chandra R; Clark AB; Hart AR; Hawk E; Kandioler D; Kappel S; Krishnadath SK; Sharma A; Singh I; Straub D; Triadafilopoulos G; Umar A; Wolf B
Ann N Y Acad Sci; 2014 Sep; 1325():108-26. PubMed ID: 25266020
[TBL] [Abstract][Full Text] [Related]
23. Chemoprevention of Barrett's Esophagus and Esophageal Adenocarcinoma.
Bresalier RS
Dig Dis Sci; 2018 Aug; 63(8):2155-2162. PubMed ID: 29948566
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett's esophagus.
Yeh RW; Gerson LB; Triadafilopoulos G
Dis Esophagus; 2003; 16(3):193-8. PubMed ID: 14641308
[TBL] [Abstract][Full Text] [Related]
25. Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end!
Scarpignato C
Neurogastroenterol Motil; 2012 Aug; 24(8):697-704. PubMed ID: 22783985
[TBL] [Abstract][Full Text] [Related]
26. 24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors.
Ortiz A; Martínez de Haro LF; Parrilla P; Molina J; Bermejo J; Munitiz V
Br J Surg; 1999 Nov; 86(11):1472-4. PubMed ID: 10583299
[TBL] [Abstract][Full Text] [Related]
27. Ask the doctor. Do PPI drugs for stomach acid reduce the risk of cancer in people (like me) with Barrett's esophagus?
Komaroff AL
Harv Health Lett; 2014 Apr; 39(6):2. PubMed ID: 24873004
[No Abstract] [Full Text] [Related]
28. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
29. Impact of gastroesophageal reflux control through tailored proton pump inhibition therapy or fundoplication in patients with Barrett's esophagus.
Baldaque-Silva F; Vieth M; Debel M; Håkanson B; Thorell A; Lunet N; Song H; Mascarenhas-Saraiva M; Pereira G; Lundell L; Marschall HU
World J Gastroenterol; 2017 May; 23(17):3174-3183. PubMed ID: 28533674
[TBL] [Abstract][Full Text] [Related]
30. [Medical treatment of Barrett's esophagus].
Kinoshita Y; Yuki T
Nihon Rinsho; 2005 Aug; 63(8):1449-53. PubMed ID: 16101238
[TBL] [Abstract][Full Text] [Related]
31. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor.
Fass R; Sampliner RE; Malagon IB; Hayden CW; Camargo L; Wendel CS; Garewal HS
Aliment Pharmacol Ther; 2000 May; 14(5):597-602. PubMed ID: 10792123
[TBL] [Abstract][Full Text] [Related]
32. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.
Masclee GM; Coloma PM; Spaander MC; Kuipers EJ; Sturkenboom MC
BMJ Open; 2015 Jan; 5(1):e006640. PubMed ID: 25633286
[TBL] [Abstract][Full Text] [Related]
33. Medication usage and the risk of neoplasia in patients with Barrett's esophagus.
Nguyen DM; El-Serag HB; Henderson L; Stein D; Bhattacharyya A; Sampliner RE
Clin Gastroenterol Hepatol; 2009 Dec; 7(12):1299-304. PubMed ID: 19523538
[TBL] [Abstract][Full Text] [Related]
34. Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.
Wani S; Sampliner RE; Weston AP; Mathur S; Hall M; Higbee A; Sharma P
Aliment Pharmacol Ther; 2005 Oct; 22(7):627-33. PubMed ID: 16181302
[TBL] [Abstract][Full Text] [Related]
35. Chemoprevention in Barrett's esophagus: are we there yet, are we there yet...?
Corley DA
Clin Gastroenterol Hepatol; 2009 Dec; 7(12):1266-8. PubMed ID: 19772949
[No Abstract] [Full Text] [Related]
36. Pharmacotherapy for chronic gastro-oesophageal reflux disease and Barrett's oesophagus.
Wurm P; de Caestecker J
Expert Opin Pharmacother; 2003 Jul; 4(7):1049-61. PubMed ID: 12831333
[TBL] [Abstract][Full Text] [Related]
37. Proton Pump Inhibitors and Radiofrequency Ablation for Treatment of Barrett's Esophagus.
Dugalic P; Djuranovic S; Pavlovic-Markovic A; Dugalic V; Tomasevic R; Gluvic Z; Obradovic M; Bajic V; Isenovic ER
Mini Rev Med Chem; 2020; 20(11):975-987. PubMed ID: 31644405
[TBL] [Abstract][Full Text] [Related]
38. Does the addition of a prokinetic to proton pump inhibitor therapy help reduce duodenogastro-oesophageal reflux in patients with Barrett's oesophagus?
Smythe A; Bird NC; Troy GP; Ackroyd R; Johnson AG
Eur J Gastroenterol Hepatol; 2003 Mar; 15(3):305-12. PubMed ID: 12610326
[TBL] [Abstract][Full Text] [Related]
39. Chemoprevention in Barrett's Esophagus: Current Status.
Zeb MH; Baruah A; Kossak SK; Buttar NS
Gastroenterol Clin North Am; 2015 Jun; 44(2):391-413. PubMed ID: 26021201
[TBL] [Abstract][Full Text] [Related]
40. [The clinical strategy for the Barrett's esophagus].
Kitabatake S; Niwa Y; Goto H
Nihon Rinsho; 2005 Aug; 63(8):1434-7. PubMed ID: 16101235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
